226. 間質性膀胱炎（ハンナ型） Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05062902 (ClinicalTrials.gov) | January 1, 2023 | 16/9/2021 | A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | Interstitial Cystitis;Chronic Pain;Pelvic Floor; Relaxation;Pelvic Floor Disorders | Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device;Drug: Botulinum Neurotoxin | HillMed Inc. | Baylor College of Medicine;University of Houston | Not yet recruiting | 18 Years | 60 Years | Female | 46 | Early Phase 1 | United States |
| 2 | NCT04734106 (ClinicalTrials.gov) | May 2022 | 27/1/2021 | Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | Interstitial Cystitis;Chronic Interstitial Cystitis;Bladder Pain Syndrome | Drug: Desert Harvest Aloe Vera Capsules;Other: Placebo Capsules | Wake Forest University Health Sciences | Desert Harvest | Not yet recruiting | 18 Years | N/A | All | 100 | Early Phase 1 | United States |
| 3 | JPRN-jRCTs051210106 | 13/10/2021 | 13/10/2021 | ESTOC study | The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial - ESTOC study | Interstitial cystitis bladder, inflammation, pain;D018856 | Participants will be randomly assigned to splatast group or control group. In splatast group, splatast tosilate capsule 100 mg (1 capsule at a time) will be orally administered 3 times a day between meals for 3 months. In control group, flavoxate hydrochloride tablets 200 mg (1 tablet at a time) will be orally administered 3 times a day between meals for 3 months. | Torimoto Kazumasa | Fujimoto Kiyohide | Recruiting | >= 20age old | Not applicable | Both | 100 | Phase 2 | Japan |
| 4 | NCT04313972 (ClinicalTrials.gov) | September 7, 2021 | 16/3/2020 | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial | Interstitial Cystitis;Painful Bladder Syndrome;Bladder Pain Syndrome;Low Dose Naltrexone;Low-dose Naltrexone;Naltrexone | Drug: low-dose naltrexone;Drug: Placebo oral tablet | NorthShore University HealthSystem | NULL | Recruiting | 18 Years | 110 Years | Female | 44 | Phase 4 | United States |
| 5 | NCT05275647 (ClinicalTrials.gov) | May 18, 2021 | 13/1/2022 | Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis | Therapeutic Efficacy and Safety of Low Energy Shock Wave (LESW) Plus Botulinum Toxin A Instillation in Treatment of Patients With Interstitial Cystitis Refractory to Conventional Therapy - A Clinical and Immunohistochemistry Study | Interstitial Cystitis | Drug: BOTOX 100U in normal saline;Drug: Normal saline | Buddhist Tzu Chi General Hospital | Ministry of Science and Technology, Taiwan;Hualien Tzu Chi General Hospital | Recruiting | 20 Years | N/A | All | 75 | Phase 2 | Taiwan |
| 6 | NCT04789135 (ClinicalTrials.gov) | March 20, 2020 | 1/3/2021 | Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis /Bladder Pain Syndrome | Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis, Chronic;Bladder Pain Syndrome | Drug: Ozone | Anhembi Morumbi University | NULL | Active, not recruiting | N/A | N/A | Female | 50 | Phase 2 | Brazil |
| 7 | NCT03844412 (ClinicalTrials.gov) | November 4, 2019 | 15/2/2019 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue Syndrome | Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pill | Duke University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 50 Years | Female | 400 | Phase 2 | United States |
| 8 | EUCTR2016-004138-12-BE (EUCTR) | 27/11/2017 | 19/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Spain;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 9 | NCT03143920 (ClinicalTrials.gov) | November 1, 2017 | 2/5/2017 | Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder | Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder: A Feasibility Trial | Chronic Interstitial Cystitis;Painful Bladder Syndrome;Recurrent Urinary Tract Infection | Combination Product: Hyperbaric Oxygen Therapy- | University of California, San Diego | NULL | Recruiting | 35 Years | 70 Years | Female | 40 | Early Phase 1 | United States |
| 10 | EUCTR2016-004138-12-GB (EUCTR) | 30/10/2017 | 17/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 11 | EUCTR2016-004138-12-NL (EUCTR) | 23/10/2017 | 24/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not Applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Latvia;Germany;Netherlands;United Kingdom | ||
| 12 | JPRN-UMIN000029113 | 2017/10/10 | 20/09/2017 | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | Patients with interstitial cystitis | Ingestion of test food including fermented buckwheat sprouts (12 weeks, 4 tablets / once a day) | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka | Kageyama Hospital (Shizuoka city)Nakamura Hospital (Beppu city) | Pending | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 13 | EUCTR2016-004138-12-PL (EUCTR) | 27/09/2017 | 19/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Belgium;Spain;Poland;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 14 | EUCTR2016-004138-12-DE (EUCTR) | 26/09/2017 | 10/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 15 | NCT03463499 (ClinicalTrials.gov) | September 22, 2017 | 25/2/2018 | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | Interstitial Cystitis | Drug: Hyaluronic Acid and Chondroitin Sulfate | Samsung Medical Center | NULL | Active, not recruiting | 20 Years | N/A | All | 62 | N/A | Korea, Republic of |
| 16 | EUCTR2016-004138-12-ES (EUCTR) | 18/09/2017 | 18/09/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 17 | EUCTR2016-004138-12-HU (EUCTR) | 14/09/2017 | 12/07/2017 | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Czech Republic;Hungary;Spain;Poland;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 18 | EUCTR2016-004138-12-CZ (EUCTR) | 30/08/2017 | 13/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 19 | EUCTR2016-004138-12-LV (EUCTR) | 04/08/2017 | 25/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Germany;Latvia;United Kingdom | ||
| 20 | EUCTR2016-000906-12-NL (EUCTR) | 15/06/2017 | 19/07/2017 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.1;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857 ;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 21 | EUCTR2016-000906-12-BE (EUCTR) | 24/04/2017 | 16/01/2017 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000017419;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 22 | NCT03104361 (ClinicalTrials.gov) | April 2017 | 3/4/2017 | Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial Cystitis | Intravesical Injections of Platelet-Rich Plasma (PRP) in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Clinical Trial | Interstitial Cystitis | Biological: Platelet-Rich Plasma | Buddhist Tzu Chi General Hospital | NULL | Not yet recruiting | 20 Years | N/A | All | 30 | Phase 1 | Taiwan |
| 23 | EUCTR2016-000906-12-ES (EUCTR) | 02/03/2017 | 16/01/2017 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.1;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 24 | NCT03008382 (ClinicalTrials.gov) | March 1, 2017 | 28/12/2016 | Interstitial Cystitis: Examination of the Central Autonomic Network | Interstitial Cystitis: Examination of the Central Autonomic Network | Interstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic Pain | Drug: Metoprolol Tartrate Oral Tablet;Drug: Placebo Oral Tablet | Medical College of Wisconsin | NorthShore University HealthSystem;Case Western Reserve University | Active, not recruiting | 18 Years | 80 Years | Female | 180 | Phase 4 | United States |
| 25 | EUCTR2016-000906-12-GB (EUCTR) | 23/11/2016 | 19/08/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 26 | EUCTR2016-000906-12-LV (EUCTR) | 11/11/2016 | 01/08/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 27 | EUCTR2016-000906-12-CZ (EUCTR) | 07/11/2016 | 27/07/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Spain;Poland;Belgium;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 28 | EUCTR2016-000906-12-HU (EUCTR) | 23/09/2016 | 27/07/2016 | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods - The LEADERSHIP 301 Trial | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Czech Republic;Hungary;Canada;Spain;Belgium;Poland;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 29 | EUCTR2016-000906-12-DK (EUCTR) | 07/09/2016 | 19/07/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 30 | JPRN-UMIN000027918 | 2016/07/01 | 25/06/2017 | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis | interstitial cystitis | heparin-lidocaine intravesical therapy | Department of Urology and Renal transplantation, Nagasaki University Hospital | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan | |
| 31 | JPRN-UMIN000026714 | 2016/02/26 | 27/03/2017 | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. | Interstitial cystitis | Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. | Department of Urology, Mitsui Memorial Hospital | NULL | Pending | 20years-old | Not applicable | Male and Female | 20 | Phase 2,3 | Japan | |
| 32 | NCT01393223 (ClinicalTrials.gov) | July 21, 2015 | 7/7/2011 | Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome | A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis | Drug: LP-08 80mg;Drug: Normal saline;Drug: LP-08 20mg | Lipella Pharmaceuticals, Inc. | William Beaumont Hospitals | Completed | 18 Years | 70 Years | All | 21 | Phase 2 | United States |
| 33 | JPRN-UMIN000014860 | 2014/10/31 | 01/09/2014 | Efficacy and safety of intravesical administration of dimethyl sulfoxide (DMSO) in interstitial patients | Efficacy and safety of intravesical administration of dimethyl sulfoxide (DMSO) in interstitial patients - Efficacy and safety of intravesical administration of dimethyl sulfoxide (DMSO) in interstitial patients | interstitial cystitis | intravesical administration of DMSO | Urology, Hokkaido University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan |
| 34 | NCT02247557 (ClinicalTrials.gov) | September 2014 | 15/9/2014 | Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis | Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study | Interstitial Cystitis | Drug: Liposome encapsulated BoNT-A;Drug: BOTOX 200U in normal saline;Drug: Normal saline | Buddhist Tzu Chi General Hospital | NULL | Completed | 20 Years | 80 Years | All | 90 | Phase 2 | Taiwan |
| 35 | JPRN-UMIN000009197 | 2014/07/01 | 01/11/2012 | Safety and efficacy of tramadol in the treatment of refractory pain of interstitial cystitis: a double-blind, placebo-controlled, randomized prospective study | interstitial cystitis | oral administration of Tramadol after randomization oral administration of placebo after randomization | Departmen of Urology, The University of Tokyo Hospital | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 90 | Not applicable | Japan | |
| 36 | NCT01990898 (ClinicalTrials.gov) | November 2013 | 18/11/2013 | Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action | Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action | Interstitial Cystitis | Drug: Cyclosporine | The Cleveland Clinic | NULL | Completed | 18 Years | 80 Years | All | 26 | Phase 2 | United States |
| 37 | EUCTR2011-004555-39-LT (EUCTR) | 10/05/2013 | 21/02/2013 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 38 | JPRN-JMA-IIA00113 | 27/02/2013 | 01/03/2013 | Multi-center clinical study on the effect of glycine for disorders of urine storage | Multi-center clinical study on the effect of glycine for disorders of urine storage | Overactive bladder, chronic prostatitis, interstitial cystitis, and nocturia | Intervention type:DRUG. Intervention1:glycine, Dose form:POWDER, Route of administration:ORAL, intended dose regimen:Oral administration of Glycine 3g, twice a day, for 8 weeks . Control intervention1:glucose, Dose form:POWDER, Route of administration:ORAL, Intended dose regimen:Oral administration of Glucose 3g, twice a day, for 8 weeks . | Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP) | Okinawa Kyodo Hospital, Kawahara Nephro-urology Clinic, Yamada Urologic Clinic, Akita Urologic Clinic, Kobe Medical Center, Kitanodai Clinic, Yokohama Motimachi Womens' Clinic LUNA, Nanbu Tokushukai Hospital, Okinawa Kokubu Hospital | Completed | >=20 YEARS | No Limit | BOTH | 160 | NOT APPLICABLE | Japan |
| 39 | NCT01969773 (ClinicalTrials.gov) | December 2012 | 22/10/2013 | Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment | Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial | Interstitial Cystitis | Drug: Botulinum toxin A;Drug: Normal saline instillation | Buddhist Tzu Chi General Hospital | NULL | Completed | 20 Years | 85 Years | All | 60 | Phase 2 | Taiwan |
| 40 | JPRN-UMIN000008484 | 2012/07/23 | 20/07/2012 | a | Interstitial cystitis/ Hypersensitive bladder syndrome | Administration of mirabegron 50mg per day for four weeks. | Department of Urology, Graduate school of medicine, University of Tokyo | NULL | Pending | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 41 | EUCTR2011-004555-39-NL (EUCTR) | 05/07/2012 | 08/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 INN or Proposed INN: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 INN or Proposed INN: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 42 | EUCTR2011-004555-39-PT (EUCTR) | 01/06/2012 | 05/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 43 | EUCTR2011-004555-39-PL (EUCTR) | 18/05/2012 | 11/04/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 44 | EUCTR2011-004555-39-BE (EUCTR) | 07/05/2012 | 19/01/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 45 | EUCTR2011-004555-39-DE (EUCTR) | 30/04/2012 | 22/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Netherlands;Latvia | ||
| 46 | EUCTR2011-004555-39-ES (EUCTR) | 26/04/2012 | 06/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 300 | Phase 2 | Portugal;Russian Federation;Germany;Czech Republic;Netherlands;Denmark;Belgium;Romania;France;Spain;Latvia;Poland | ||
| 47 | EUCTR2011-004555-39-LV (EUCTR) | 20/04/2012 | 01/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 300 | Phase 2 | Portugal;Germany;Netherlands;France;Italy;Latvia;Czech Republic;Russian Federation;Belgium;Denmark;Romania;Spain;Poland | ||
| 48 | EUCTR2011-004555-39-DK (EUCTR) | 17/04/2012 | 17/04/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 49 | EUCTR2011-004555-39-CZ (EUCTR) | 13/04/2012 | 15/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 50 | JPRN-UMIN000006387 | 2011/11/01 | 31/10/2011 | Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis | interstitital cystitis | Intravesical instillation of heparin, lidocain and bicarbonate | University of Tokushima | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Phase 2 | Japan | |
| 51 | NCT01475253 (ClinicalTrials.gov) | November 2011 | 3/11/2011 | Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis | A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: Lidocaine Releasing Intravesical System - LiRIS®;Other: LiRIS Placebo;Procedure: Sham Cystoscopy Procedure | Allergan | TARIS Biomedical, Inc. | Terminated | 18 Years | N/A | Female | 104 | Phase 2 | United States;Canada |
| 52 | NCT05223244 (ClinicalTrials.gov) | October 1, 2011 | 24/1/2022 | Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC | Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized Trial | Interstitial Cystitis;Painful Bladder Syndrome | Drug: bupivacaine, triamcinolone, and heparin (BTH);Drug: dimethyl sulfoxide (DMSO) | NorthShore University HealthSystem | NULL | Completed | 18 Years | N/A | Female | 83 | Phase 4 | NULL |
| 53 | EUCTR2010-021556-25-IT (EUCTR) | 24/02/2011 | 04/11/2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Interstitial Cystitis MedDRA version: 9.1;Level: HLGT;Classification code 10018188 | Trade Name: RIMSO 50 INN or Proposed INN: Dimethyl sulfoxide | IBSA | NULL | Not Recruiting | Female: yes Male: no | Phase 3 | Italy | |||
| 54 | EUCTR2009-018118-21-CZ (EUCTR) | 09/08/2010 | 10/06/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Hungary;Czech Republic;Germany;United Kingdom | |||
| 55 | EUCTR2009-018118-21-HU (EUCTR) | 04/08/2010 | 21/05/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom | |||
| 56 | EUCTR2009-018118-21-GB (EUCTR) | 28/07/2010 | 11/06/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Czech Republic;Hungary;Germany;United Kingdom | ||
| 57 | NCT01150565 (ClinicalTrials.gov) | July 2010 | 23/6/2010 | Safety Study of LiRIS in Interstitial Cystitis (IC) Patients | Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: LiRIS low dose and LiRIS high dose | Allergan | TARIS Biomedical, Inc. | Completed | 18 Years | N/A | Female | 18 | Phase 1 | Canada |
| 58 | EUCTR2009-014597-17-SE (EUCTR) | 03/05/2010 | 28/10/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Spain;Belgium;Germany;Sweden | ||
| 59 | NCT01195116 (ClinicalTrials.gov) | May 2010 | 13/8/2010 | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: Dexmedetomidine;Drug: Normal Saline | University of Rochester | NULL | Completed | 18 Years | N/A | All | 41 | Phase 4 | United States |
| 60 | EUCTR2009-014597-17-FI (EUCTR) | 24/03/2010 | 04/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 61 | EUCTR2009-014597-17-DE (EUCTR) | 19/03/2010 | 03/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 62 | EUCTR2009-014597-17-ES (EUCTR) | 08/02/2010 | 12/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Belgium;Spain;Germany;Sweden | ||
| 63 | EUCTR2009-014597-17-SK (EUCTR) | 03/02/2010 | 11/02/2010 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 64 | NCT00823030 (ClinicalTrials.gov) | January 2009 | 14/1/2009 | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Interstitial Cystitis | Procedure: Urodynamic study;Drug: Lidocaine;Other: Normal Saline | North Shore Long Island Jewish Health System | NULL | Withdrawn | 18 Years | 80 Years | Both | 0 | N/A | United States |
| 65 | EUCTR2008-002421-37-DK (EUCTR) | 13/11/2008 | 15/08/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD 0299685 Product Name: PD 0299685 | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | Finland;Germany;Denmark;France | ||
| 66 | EUCTR2008-002421-37-FI (EUCTR) | 23/10/2008 | 02/09/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD 0299685 Product Name: PD 0299685 | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | Finland;Germany;Denmark;France | ||
| 67 | EUCTR2008-002421-37-FR (EUCTR) | 07/10/2008 | 26/08/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS). MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD-0299685 Product Name: PD-0299685 | Pfizer Ltd;Ramsgate Road,Sandwich,Kent CT13 9NJ | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | France;Finland;Denmark;Germany | ||
| 68 | JPRN-UMIN000001253 | 2008/07/01 | 16/07/2008 | A randomized trial to asses the effects of hydrogen-rich dissolution water in patients with interstitial cystitis | Interstitial cystitis | The patients will be intervened with hydrogen dissolution water group (hydrogen group) 200ml every three times in a day in 2 months (56days). After that, the patients in hydrogen dissolution water group will be transferred to the additional intervention term after the end of intervention. And after that, the patients will be randomized to withdrawal terms for more 1 month with hydrogen dissolution water or with placebo water. The patients will be intervened with normal water (placebo group) 200ml every three times in a day in 2 months (56days) After that, the patients in placebo water group will be given hydrogen water for more 1 month. | Koushinkai Hospital | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 30 | Phase 2,3 | Japan | |
| 69 | EUCTR2007-005164-27-NL (EUCTR) | 22/02/2008 | 17/10/2007 | Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis | Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis | Interstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC. | Trade Name: Botox | research office urology VUmc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Netherlands | |||
| 70 | NCT00275379 (ClinicalTrials.gov) | August 2006 | 9/1/2006 | Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis | Cystitis, Interstitial | Drug: ERB-041 | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Withdrawn | 18 Years | N/A | Female | 0 | N/A | United States;Austria;Germany |
| 71 | EUCTR2005-003367-23-DE (EUCTR) | 13/02/2006 | 23/11/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden | ||
| 72 | EUCTR2005-003367-23-DK (EUCTR) | 06/02/2006 | 21/12/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Denmark;Germany;Sweden | ||
| 73 | EUCTR2005-003367-23-SE (EUCTR) | 01/02/2006 | 06/12/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden | ||
| 74 | NCT00253006 (ClinicalTrials.gov) | January 2006 | 11/11/2005 | Analysis of Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium | A Quantitative Analysis of Protein- and mRNA-Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium | Interstitial Cystitis;Bladder Diseases;Urinary Incontinence | Procedure: Tissue examination for protein- and mRNA-expression of NO | Copenhagen University Hospital at Herlev | Roskilde County Hospital | Terminated | 18 Years | N/A | Both | 60 | N/A | Denmark |
| 75 | EUCTR2005-000890-23-SE (EUCTR) | 13/10/2005 | 02/08/2005 | NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine. | NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine. | Interstitiell cystit | Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral INN or Proposed INN: Ciklosporin | Ingrid Ehrén | NULL | Not Recruiting | Female: yes Male: yes | 15 | Sweden | |||
| 76 | JPRN-UMIN000003172 | 2005/05/01 | 12/02/2010 | Clinacal study on the intravesical instillation of dimethylsulfoxide (DMSO) for the patients with interstitial cystitis | Interstitial cystitis | Intravesical instillation of DMSO | Deparment of Urology, Medical Science, University of Fukui | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 30 | Not applicable | Japan | |
| 77 | JPRN-UMIN000027494 | 2004/07/20 | 25/05/2017 | Intravesical administration of Dimethyl sulfoxide(DMSO) for patients with Interstitial cystitis | Intravesical administration of Dimethyl sulfoxide(DMSO) for patients with Interstitial cystitis - Dimethyl sulfoxide(DMSO) for patients with Interstitial cystitis | Interstitial cystitis | Intravesical DMSO administration (50%, 50ml),2weeks every, 8 times | Department of Urology, Hamamatsu University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Not applicable | Japan |
| 78 | NCT00194610 (ClinicalTrials.gov) | May 2004 | 13/9/2005 | Botox as a Treatment for Interstitial Cystitis in Women | Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial | Painful Bladder Syndrome;Interstitial Cystitis | Drug: Botox;Other: normal saline | University of Washington | Paul G. Allen Family Foundation | Completed | 18 Years | N/A | Female | 20 | Phase 4 | United States |
| 79 | EUCTR2008-002421-37-DE (EUCTR) | 29/07/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD 0299685 Product Name: PD 0299685 | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 147 | Phase 2 | Finland;Germany;Denmark;France | |||
| 80 | EUCTR2009-018118-21-DE (EUCTR) | 10/05/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom |